Stocks · News reference
SELLAS Life Sciences Group shares are trading lower Wednesday as investors take profits, with risk appetite softer across equities.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.